B-cell non-Hodgkin lymphoma

This study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell non-Hodgkin lymphoma. The goal is to see if this mix can shrink tumors or stop the cancer from growing. About 36 adults who have already tried o…

This early-phase trial is testing an experimental cell therapy called GT719 in 46 adults with relapsed or treatment-resistant B-cell lymphoma or leukemia that tests positive for CD19. The study aims to see if the treatment is safe and how well it works. Participants receive a sin…

This Phase 2 trial is testing a new drug called MEN1703, both alone and combined with another drug called glofitamab, in 178 adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The study aims to see if the drugs…

This early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are…

This study tests a new type of CAR-T cell therapy, called UCD19 CAR-T, in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) or B-cell non-Hodgkin lymphoma (B-NHL) that has come back or not responded to standard treatment. The therapy is made locally to sp…

This Phase 2 trial is testing an investigational drug called surovatamig (AZD0486) in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and large B-cell lymphoma. Participants must have tried at least two prior treatments. The study aim…

This study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …

This early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combinat…

This early-stage trial is testing a new drug called JNJ-95566692, a trispecific antibody designed to target lymphoma cells. It is given alone or with another drug (JNJ-87801493) to about 130 people whose B-cell non-Hodgkin lymphoma has not responded to or returned after at least …

This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …

This early-stage trial tests a new type of immune cell therapy for people with several kinds of blood cancers that have come back or stopped responding to treatment. The therapy uses natural killer (NK) cells from donated cord blood, which are genetically modified to better recog…

This study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…

This early-stage trial tests an experimental drug called ARV-393 in 255 adults with advanced non-Hodgkin's lymphoma that has come back or not responded to other treatments. The drug is taken as a pill and works by breaking down a protein that helps lymphoma grow. The main goals a…

This study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This study tests a new way to do a stem cell transplant for children with a hard-to-treat type of leukemia (ALL). Doctors will use special immune cells (CAR T cells) after the transplant to try to kill any remaining cancer cells. The goal is to see if this approach is safe and wo…

This study is testing two experimental treatments, KITE-363 and KITE-753, for people with B-cell lymphoma that has returned or stopped responding to standard therapy. These are personalized cell therapies made from a patient's own immune cells, engineered to attack two targets (C…

This study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer). The goal is to find safe doses and check if the drug shrinks tumors. About 91 participants will take part …

This study tests a new CAR-T therapy made from donor cells, so it's ready to use without waiting for a patient's own cells to be modified. It targets two proteins on cancer cells to lower the chance of the cancer coming back. About 178 adults with relapsed or refractory B-cell ly…

This study tests a new drug called ARC-02, given together with rituximab, in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least two prior treatments. The main goals are to check the safety of ARC-02 and find the best dose, while also looking at whe…

This early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…

This study tests a new drug called TORL-5-700, given alone or with other medicines, for people with B-cell Non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to find a safe dose and see if it can shrink tumors. About 155 adults will take part …

This trial tests a new drug called DS3790a for people with certain blood cancers, including B-cell non-Hodgkin lymphoma. The drug is designed to find and attack cancer cells while sparing healthy ones. The study will check safety and how well it works in about 420 adults.

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This early-phase study tests a new approach for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. Participants receive their own immune cells that have been modified to attack cancer cells, along with specially edited stem …

This trial tests a new drug called SHR-3079 in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least one prior standard treatment. The main goals are to check the drug's safety, find the best dose, and get an early look at whether it can shrink tumors…

This study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. The drug works like a guided missile, targeting a protein (CD19) on cancer cells to deliver a toxic payload. The study aims to find…

This early-phase study tests a new treatment called JV-213 for adults with B-cell lymphoma that has come back or not responded to other treatments. JV-213 uses the patient's own immune cells, modified to attack cancer cells. The main goal is to find the safest dose and monitor si…

This early-phase trial tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…

This early-phase study is testing a new cell therapy called GT801 in 28 adults with relapsed or hard-to-treat B-cell blood cancers (like leukemia and lymphoma) or autoimmune hemolytic anemia (AIHA). The therapy uses a patient's own immune cells, modified to attack CD19-positive c…

This early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safe…

This early-phase trial tests whether the drug pomalidomide can improve the effects of CAR T-cell therapy in people with B-cell leukemias or lymphomas that have returned or not responded to treatment. The study will enroll 12 adults who have already received CAR T-cell therapy. Re…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This study tests a CAR-T cell therapy (axicabtagene ciloleucel) in 20 HIV-positive adults whose aggressive B-cell lymphoma has come back or stopped responding to standard treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells. The …

This early-phase study tests a new type of immunotherapy called CD19x22 CAR T cells for teenagers and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer …

This phase II trial tests whether combining epcoritamab (an immunotherapy that directs immune cells to kill lymphoma) with lenalidomide (which boosts the immune system) can shrink tumors in 34 patients whose immunodeficiency-related large B-cell lymphoma has not responded to trea…

This early-phase trial is testing an oral drug called BTM-3566 in 24 adults with relapsed or refractory B-cell lymphoma. The main goals are to find a safe dose and see if the drug can slow or stop the cancer. Participants take the drug for 7 days, then have 7 days off, and visit …

This early-stage trial tests a new treatment called IBR900, made from natural killer (NK) cells, for people with a type of blood cancer called CD20-positive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The study has two parts: first, finding t…

This early-stage trial is testing a new drug called MK-1045 (CN201) in about 100 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. MK-1045 is an immunotherapy designed to help the immune system fight the cancer. The main goals are to check …

This early-phase trial tests a new type of immune cell therapy for patients with EBV-positive Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard treatments. The researchers add a gene called C7R to the patient's own T cells to help them survive longer …

This study is for adults with B-cell or T-cell lymphoma that has returned or stopped responding to at least two prior treatments. The drug, STP938, blocks a protein cancer cells need to grow. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it …

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This early-phase trial is testing a new cell therapy called TBI-2001 for people with certain blood cancers (B-cell lymphoma, CLL, SLL) that have come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to recognize and a…

This early-stage trial tests a new treatment called IC19/1563 for people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recogn…

This study is testing whether adding the drug rituximab early and intensively to a strong chemotherapy regimen can improve outcomes for children and teens with aggressive B-cell non-Hodgkin lymphoma. About 87 participants will receive the combination therapy. The goal is to see i…

This study tests whether adding a drug called golcadomide after standard CAR T-cell therapy can prevent aggressive large B-cell lymphoma from returning in patients at high risk of relapse. About 65 adults will receive golcadomide for 24 weeks starting 5 days after their CAR T-cel…

This early-stage trial tests an experimental drug called REGN5837 combined with the approved drug odronextamab for people with aggressive B-cell lymphoma that has come back or not responded to prior treatments. The study first finds a safe dose, then checks how well the combo wor…

This early-stage study is testing a new gene therapy that reprograms a patient's own immune cells to attack two targets (CD19 and CD20) on cancer cells. The trial will enroll 30 adults with B-cell cancers that have come back or not responded to treatment. The main goals are to ch…

This early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…

This early-stage trial is testing a new treatment called U01 (ssCART-19) for people with B-cell lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will enroll 30 p…

This early-stage study tests a new drug called LP-284 in about 110 adults whose lymphomas or solid tumors have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug move…

This study tests a new combination of drugs (CD19 t-haNK, N-803, and rituximab) in 20 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors and improve survival. Particip…

This study tests whether a special type of immune cell (ONC-PluReceptor NK cells) given with two antibody drugs (epcoritamab and tafasitamab) can control B-cell Non-Hodgkin lymphoma that has come back or not responded to prior treatments. About 30 adults aged 18-80 who have alrea…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This early-phase trial tests whether adding the oral drug selinexor to standard chemotherapy can help people with relapsed or refractory B-cell non-Hodgkin lymphoma that has spread to the central nervous system. About 37 adults will receive the combination to find the safest dose…

This phase 2 trial tests whether adding epcoritamab, a bispecific antibody that helps the immune system attack cancer cells, to standard chemotherapy (EPOCH-R) is safe and effective for aggressive B-cell non-Hodgkin lymphoma. About 18 patients with hard-to-treat forms of the dise…

This early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…

This study looks at whether CAR T cell therapy, a type of cancer treatment that uses a patient's own immune cells, can be safely given to people with moderate to severe kidney problems. The trial involves 20 adults with blood cancers like lymphoma, myeloma, or leukemia. Before ge…

This study tests a new treatment called TranspoCART19 for people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are genetically modified to better recognize and attack cancer cells. The trial wi…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This study tests a personalized CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. Patients' own immune cells are collected, modified to target cancer cells, and infused back. The trial has two phases: first to find the safest dos…

This study is testing a new type of cell therapy called CD19/CD20 CAR/TRuC-T for people with B-cell lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cance…

This early-phase study tests a new type of immune cell therapy (CD19 t-haNK) alone or with two other drugs (N-803 and rituximab) in up to 20 adults with relapsed or refractory non-Hodgkin lymphoma. The main goal is to check safety, and researchers will also see if the treatment s…

This early-phase study tests a new drug called IMV101 in 30 adults whose B-cell non-Hodgkin lymphoma has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the …

This early-phase trial is testing a new version of CAR T-cell therapy that has been modified to improve its energy use, potentially making the cells more effective. It is for adults with certain types of B-cell lymphoma or chronic lymphocytic leukemia that have come back or not r…

This study tests whether giving cancer patients a targeted therapy that matches a specific gene change in their tumor can help shrink or control the cancer. It includes 720 adults with advanced solid tumors, multiple myeloma, or non-Hodgkin lymphoma who have no standard treatment…

This early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…

This early-phase trial tests a new approach for people with intermediate or high-grade B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It combines specially engineered immune cells (CAR T cells) that target cancer cells with a vaccine designed to boo…

This early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is t…

This study tests a new way to make immune cells (called GRALE T cells) that are trained to attack cells infected with the Epstein-Barr virus (EBV), which is linked to some lymphomas. The trial includes people with Hodgkin or non-Hodgkin lymphoma, or related diseases, whose cancer…

This study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. The goal is to see if this combo can …

This early-stage trial tests a new type of CAR-T cell therapy called BAFF-R CAR-T for adults with a specific kind of B-cell lymphoma that has stopped responding to treatment and does not have the CD19 marker. The study will enroll 30 people to see if the treatment is safe and tol…

This early-phase trial is testing whether adding two drugs—CC-99282 and rituximab—can help people with non-Hodgkin lymphoma who didn't get a good result from CAR T-cell therapy. The study will enroll 18 adults with relapsed or refractory B-cell lymphoma. Researchers are looking f…

This early-phase trial is testing whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) after a stem cell transplant can safely help prevent B-cell non-Hodgkin lymphoma from returning. About 15 people with intermediate or high-…

This study is for children and young people with B-cell Non-Hodgkin lymphoma that has come back or not responded to treatment. Current treatments are harsh and only work for about 30 out of 100 children. The trial will test several new medicines, alone or with chemotherapy, to se…

This early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called …

This phase II trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and ATRA (a vitamin A derivative)—in 24 adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and can shrink tumors. Participants…

This early-phase study tests a new approach for patients with B-cell lymphoma that has not responded to standard treatments. A specially designed virus is injected to deliver instructions that turn some of the patient's own immune cells into cancer-killing cells directly inside t…

This study tests a new treatment called BAFFR CAR-T for people with B-cell blood cancers that have returned or not responded to standard therapy. The therapy uses a patient's own immune cells, modified to attack cancer cells. The goal is to see if it is safe and helps control the…

This study tests a new treatment called SHB-04-CD22, which uses a patient's own immune cells (T-cells) engineered to find and attack cancer cells that have a protein called CD22. It is for children and adults (ages 1-80) with B-cell cancers that have come back or not responded to…

This study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …

This study tests a new treatment for people with advanced B-cell lymphoma or leukemia that has returned or not improved after standard therapy. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and also add extra…

This study is testing whether giving a special immune cell treatment (CAR-T) right after a stem cell transplant can help people with aggressive B-cell lymphoma that has not responded to standard treatments. The trial will enroll 16 people and measure how many achieve complete rem…

This early-phase trial is testing an experimental immune cell therapy called GT719 in 34 adults with relapsed or refractory CD19-positive B-cell blood cancers (certain leukemias and lymphomas). The treatment uses specially engineered cells to target and destroy cancer cells. The …

This program provides compassionate use of odronextamab for people with relapsed or refractory follicular lymphoma, diffuse large B-cell lymphoma, or other B-cell non-Hodgkin lymphomas who have no other treatment options. Odronextamab is a drug that helps the immune system attack…

This early-stage study tests an experimental drug called SAR448501 in about 96 adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goal is to find the safest and most effective dose by monitoring side effects …

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma, lymphoma, or leukemia. Researchers will track side effects, cancer return, and overall health for years. The goal is to understand the long-term safety and effec…

This early-stage study tests a new treatment called BRL-201 for people with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to target cancer cells, and aims to control the disease. About 12-18 adults will participate to …

This early study tests a one-time treatment using universal (off-the-shelf) CAR-T cells that target CD19, a protein on cancer cells. It is for adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have few options left. The main goal is to check safety and find the r…

This early-phase study tests a new type of CAR T-cell therapy for adults with blood cancers like leukemia, lymphoma, and multiple myeloma that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack canc…

This early-phase trial is testing a new type of immune cell therapy called BAFFR-CAR T cells for people with relapsed or refractory B-cell Non-Hodgkin's lymphoma. The study aims to find a safe dose and check for side effects. About 36 adults whose cancer has not responded to prio…

This early-stage trial tests a new therapy made from cord blood immune cells (CAR NK cells) designed to target and kill B-cell lymphoma cells. It is for patients whose cancer has not responded to or has returned after standard treatments. The study will check safety and how well …

This early-stage trial is testing a new drug, BR111, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug might slow or shrink tum…

This early-phase trial tests a new drug called ZZSW-01 in 6 people with B-cell blood cancers that have come back or not responded to other treatments. The drug is a special particle that carries instructions for the body to make its own cancer-fighting cells. The main goal is to …

This early-stage study is testing a new immune cell therapy called CT1190B CAR-T in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatments. The goal …

This early-stage study is testing a new biologic drug called CC312 in 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check safety and find the right dose. Participants receive CC31…

This study tests an online cognitive training program called I-CAN in 90 adults with relapsed multiple myeloma or B-cell non-Hodgkin lymphoma who are about to receive CAR-T cell therapy. The training aims to reduce the memory, attention, and thinking problems that often follow ca…

This study tests whether a geriatric assessment—checking physical function, thinking skills, and nutrition—followed by tailored support (physical therapy, delirium prevention, and nutritional help) can help people aged 60 and older recover faster after CAR-T therapy for B-cell no…

This observational study is recruiting 300 active-duty service members and military beneficiaries diagnosed with B-cell non-Hodgkin lymphoma. Researchers want to understand how exposure to toxins, genetic differences, and immune system problems are linked to this cancer. Particip…

This pilot study is testing whether fecal microbiota transplantation (FMT) — giving processed stool from a healthy donor via enema — is safe and doable in 20 patients with lymphoma or leukemia who are receiving CAR-T therapy or stem cell transplants. The goal is to see if at leas…

This study observes older patients (60+) receiving standard CAR-T therapy for blood cancers. Researchers track how treatment affects daily activities, thinking skills, and overall quality of life. No extra treatments are given—just careful monitoring to learn more about patient e…

This study is testing a new combination of blood tests, scans, and health checks to see if it can predict which lymphoma patients will respond well to CAR T cell therapy. Researchers will follow 50 patients with relapsed or hard-to-treat B-cell lymphoma who are already scheduled …

This study follows 1,500 people with B-cell non-Hodgkin lymphoma in Italy who are treated with newer monoclonal antibodies. Researchers will track how well the cancer responds, how long patients live without the disease getting worse, and any side effects. The goal is to see how …

This study is observing 130 adults with B-cell non-Hodgkin lymphoma who are scheduled to receive CAR-T cell therapy. Researchers want to see if having low muscle mass (sarcopenia) affects how well the treatment works or causes more side effects. The goal is to learn whether simpl…

This study follows 500 people who received CAR-T cells in earlier trials for blood cancers like lymphoma and multiple myeloma. Researchers will check for new cancers and track long-term safety and effectiveness over 15 years. No new treatment is given; it is purely an observation…